gene in people relapsing following cure with the BCL2 antagonist venetoclax. 66 Resistance to those agents has become connected to these mutations in all around 70% of cases, Even though they tend to be subclonal and their specific position resulting in resistance should be verified.Over the past decades, the amount of clients referred for allogene